English translation of content medically reviewed in Romanian by Dr. Claudiu Ruscu, intensive care physician (anaesthesia & intensive care)· Romanian text reviewed 20 September 2026
850RON
Consultation included if you go ahead · otherwise 200 RON
or message us on WhatsAppCertified doctors · Payment at the clinic
An intermediate-dose iron infusion, given only at the clinic with continuous monitoring (blood pressure, oxygen saturation, pulse and ECG). Given ONLY on the basis of blood tests confirming the deficiency — ferritin, serum iron and full blood count, plus C-reactive protein where relevant — and after a medical assessment. It takes about 1.5 hours, infusion and observation. The effect on anaemia shows at least two weeks after the infusion, not immediately.
Read the medical guide first — when it is indicated, which tests it requires and how long it takes to see an effect.
Given exclusively at the clinic, not at home, and only after a medical assessment. See all prices.

For most people with iron deficiency, oral supplementation is the first option. The intravenous route is decided at the assessment, on the basis of blood tests.
The full list of contraindications is discussed during the consultation.
Iron sucrose — 300 mg iron
The dose is adjusted individually, based on the medical consultation. Every substance is pharmaceutical grade, given intravenously for higher bioavailability.
Iron infusions are given only at the clinic and only on the basis of blood tests confirming the deficiency (ferritin, serum iron, full blood count, plus C-reactive protein where relevant), after a medical assessment. They are not given on request and are not given at home.
We assess your health and decide whether this protocol is right for you.
You are seated comfortably. The IV cannula is placed and monitoring begins.
The infusion is given slowly, under medical monitoring, for optimal tolerability.
Afterwards you stay at the clinic for the observation period, under monitoring.
Ferritin, serum iron and a full blood count, plus C-reactive protein when an inflammatory process is suspected. Without them the infusion is not given, because ferritin is an acute-phase reactant and can mask a real deficiency.
No. It is given only at the clinic, because intravenous iron can cause hypersensitivity reactions and requires emergency equipment and an observation period after the infusion.
After at least two weeks. The iron has to be incorporated into newly formed red blood cells, and red blood cell production (erythropoiesis) takes time. This is not a protocol you feel on the day it is given.
Blood pressure, oxygen saturation, pulse and ECG, continuously throughout. The patient also stays at the clinic after the infusion has finished.
English translation of answers medically reviewed in Romanian. They do not replace a consultation — indications and contraindications are decided individually, at the medical assessment.
The studies below support the statements on mechanism, pharmacokinetics and safety on this page. They do not support a guaranteed therapeutic outcome — each one is followed by its limitation.
[1] Pasricha SR, Tye-Din J, Muckenthaler MU, et al. Iron deficiency. Lancet. 2021.
narrative review · PMID 33285139
Limitation: A narrative review (a Lancet seminar), with no systematic method and no new data. The recommendation to try oral iron first is expert opinion, not the result of a direct oral vs IV comparison in the clinic's population (adults without chronic inflammatory disease).
[2] Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015.
meta-analysis · sample: 6831 · PMID 25700159
Limitation: It analyses only ferrous sulphate, not other, better-tolerated oral salts. Heterogeneity is moderate to high, and the definitions of digestive side effects differ between studies. Two authors hold a patent on an alternative iron preparation.
[3] Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015.
meta-analysis · PMID 25572192
Limitation: It includes studies from 1965–2013, with older preparations and very different populations (kidney disease, heart failure). The randomised trials have little power for rare events such as anaphylaxis, and data after 2013, for carboxymaltose, are missing.
[4] Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014.
narrative review · PMID 25420283
Limitation: It is an expert consensus guideline, not new data: the frequencies are taken from other sources. PubMed labels it “Meta-Analysis”, but it is in fact a review with recommendations. The conflict-of-interest statements need to be read in the article.
[5] Wolf M, Rubin J, Achebe M, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020.
randomised trial · sample: 245 · PMID 32016310
Limitation: Open-label (not blinded) trials, funded by Pharmacosmos, the maker of ferric derisomaltose (Monofer), the direct competitor. Carboxymaltose was given twice at 750 mg (1500 mg in total), more than the 500 mg protocol. The outcome is biochemical, followed for 35 days, and its clinical importance has not been established.
[6] Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021.
meta-analysis · PMID 33188534
Limitation: The comparison is between different studies, not direct within the same study, with different doses and definitions of hypophosphataemia. The authors received fees from both manufacturers (Pharmacosmos, Vifor), and follow-up is at most 3 months.
[7] Namaste SM, Rohner F, Huang J, et al. Adjusting ferritin concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr. 2017.
meta-analysis · sample: 24844 · PMID 28615259
Limitation: These are population surveys, mainly from low- and middle-income countries, of children and young women. The study adjusts prevalence at population level and does not provide thresholds for individual diagnosis in the clinic.
Indications, studies and frequently asked questions: the complete guide to Iron infusion — 300 mg protocol.
850 RON · consultation included if you go ahead · only on the basis of blood tests
We use necessary cookies and, only with your consent, analytics and marketing cookies.We use cookies to improve your experience on this site. Strictly necessary cookies are always on. You can also accept analytics and marketing cookies, or decline them. Details